TSX Exchange Symbol: RVX
CALGARY, Oct. 21 /PRNewswire-FirstCall/ - Resverlogix Corp.
("Resverlogix") (TSX:RVX) announced today that the ongoing double blind
placebo controlled Phase 1b/2a study in subjects with normal and low HDL is
progressing as planned. The subjects in the first group receiving a low
dose of RVX-208 show safety and tolerability. Thus the safety committee the
has made a decision to commence the next cohort in which 24 subjects will
receive treatment doses escalating each week, for a total of 4 weeks.
Donald J. McCaffrey, President and CEO of Resverlogix stated, "We are
very pleased to be able to share this exciting clinical information with
the Clinical Advisory Board at the American Heart Association meeting on
November 8th."
Resverlogix will give an oral presentation during the American Heart
Association Scientific Sessions meeting in November 2008 where the Company
will present novel data for RVX-208 to attendees. Due to the nature of
double blinded clinical trials and strict embargo rules set by the American
Heart Association, data from this Phase 1b/2a clinical trial will not be
presented in full until the completion of the trial.
About RVX-208
RVX-208, a novel small molecule therapeutic that facilitates endogenous
ApoA-I production, is positioned to be one of the most promising emerging
drugs in the treatment of atherosclerosis. To the Company's knowledge
RVX-208 is the only novel small molecule that is specifically designed to
increase ApoA-I production and thereby raise HDL levels thus enhancing HDL
functionality to augment reverse cholesterol transport (RCT).
RCT is a pathway by which accumulated cholesterol is transported from
the arterial wall to the liver for excretion, thus preventing
atherosclerosis. Major constituents of RCT include acceptors such as
high-density lipoprotein (HDL) and apolipoprotein A-I (ApoA-I). A critical
part of RCT is cholesterol efflux, in which accumulated cholesterol is
removed from macrophages.
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets with
significant unmet needs. The NexVas(TM) program is the Company's primary
focus which is to develop novel small molecules that enhance ApoA-I. These
vital therapies address the grievous burden of atherosclerosis and other
important diseases such as acute coronary syndrome, diabetes, Alzheimer's
disease and other vascular disorders. The Company's secondary focus is
TGF-Beta Shield(TM), a program that aims to address burgeoning grievous
diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the
Toronto Stock Exchange (TSX:RVX). For further information please visit
http://www.resverlogix.com.
This news release may contain certain forward-looking statements that
reflect the current views and/or expectations of Resverlogix Corp. with
respect to its performance, business and future events. Such statements are
subject to a number of risks, uncertainties and assumptions. Actual results
and events may vary significantly. The TSX Exchange does not accept
responsibility for the adequacy or accuracy of this news release.
SOURCE Resverlogix Corp.
 back to top
CONTACT:
Theresa Kennedy, VP, Corporate
Communications, Resverlogix Corp., Phone: (604) 538-7072, Fax:
(403) 256-8495, Email: Theresa@resverlogix.com; Sarah Zapotichny,
Manager, Investor Relations, Resverlogix Corp., Phone: (403)
254-9252, Fax: (403) 256-8495, Email: Sarah@resverlogix.com;
Website: http://www.resverlogix.com
|
